Foamix Pharmaceuticals (FOMX) Scheduled to Post Quarterly Earnings on Monday
Foamix Pharmaceuticals (NASDAQ:FOMX) is scheduled to be announcing its earnings results after the market closes on Monday, November 11th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.
Foamix Pharmaceuticals (NASDAQ:FOMX) last released its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.07). Foamix Pharmaceuticals had a negative return on equity of 75.99% and a negative net margin of 2,115.11%. On average, analysts expect Foamix Pharmaceuticals to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
FOMX opened at $4.34 on Friday. The stock has a market capitalization of $235.48 million, a PE ratio of -2.55 and a beta of 1.57. The company’s 50 day simple moving average is $3.15 and its 200 day simple moving average is $2.85. Foamix Pharmaceuticals has a 1 year low of $1.97 and a 1 year high of $4.55.
In related news, CFO Ilan Hadar sold 9,420 shares of Foamix Pharmaceuticals stock in a transaction on Monday, September 9th. The shares were sold at an average price of $3.50, for a total value of $32,970.00. Following the completion of the sale, the chief financial officer now owns 123,671 shares in the company, valued at $432,848.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.95% of the stock is currently owned by insiders.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Further Reading: What causes a recession?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.